Pacific Biosciences of California Inc (PACB, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $41.95 million, and the earnings are expected to come in at -$0.24 per share. The full year 2024's revenue is expected to be $166.51 million and the earnings are expected to be -$1.29 per share. More detailed estimate data can be found on the Forecast page.
Pacific Biosciences of California Inc (PACB, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Pacific Biosciences of California Inc (PACB) have declined from $178.56 million to $166.51 million for the full year 2024 and from $230.84 million to $212.28 million for 2025. Earnings estimates for the same periods have also shown fluctuations; the full year 2024 estimates declined from -$0.94 per share to -$1.29 per share, while the 2025 estimates slightly improved from -$0.75 per share to -$0.74 per share.
Pacific Biosciences of California Inc (PACB, Financial) Reported History
In the previous quarter of 2024-06-30, Pacific Biosciences of California Inc's (PACB) actual revenue was $36.01 million, which missed analysts' revenue expectations of $40.878 million by -11.9%. Pacific Biosciences of California Inc's (PACB) actual earnings were -$0.64 per share, which missed analysts' earnings expectations of -$0.238 per share by -168.91%. After releasing the results, Pacific Biosciences of California Inc (PACB) was up by 9.15% in one day.
Pacific Biosciences of California Inc (PACB, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 12 analysts, the average target price for Pacific Biosciences of California Inc (PACB) is $2.92 with a high estimate of $7 and a low estimate of $1. The average target implies an upside of 14.38% from the current price of $2.55.
Based on GuruFocus estimates, the estimated GF Value for Pacific Biosciences of California Inc (PACB, Financial) in one year is $10.79, suggesting an upside of 323.14% from the current price of $2.55.
Based on the consensus recommendation from 15 brokerage firms, Pacific Biosciences of California Inc's (PACB, Financial) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
